West Pharma reports record FY2021 sales $2.832B (+32%), guides FY2022 EPS $9.20-$9.35

WEST PHARMACEUTICAL SERVICES INC

2021-FY EPS reported $8.67 revenue$2,831,600,000

Q4 net sales $730.8M (+26%), organic +28.3%; full-year sales $2.832B (+31.9%), organic +29.4%.
Full-year reported diluted EPS $8.67 (+90%); adjusted diluted EPS $8.58 (+80%).
Proprietary Products segment Q4 sales $609.3M (+34.2%), driven by high-value product growth across all market units.
FY2022 guidance: net sales $3.050-$3.075B (~10% organic growth), reported EPS $9.20-$9.35, capex $380M.
Operating cash flow $584M (+23.6%), free cash flow $330.6M (+10.9%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.